 Connection
David Simpson to Treatment Outcome
This is a "connection" page, showing publications David Simpson has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.267 |
|
|
|
-
Wissel J, Cam?es-Barbosa A, Comes G, Althaus M, Scheschonka A, Simpson DM. Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis. Toxins (Basel). 2021 Dec 11; 13(12).
Score: 0.075
-
Jog M, Lee J, Scheschonka A, Chen R, Ismail F, Boulias C, Hobson D, King D, Althaus M, Simon O, Dersch H, Frucht S, Simpson DM. Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study. Toxins (Basel). 2020 Dec 20; 12(12).
Score: 0.070
-
Bensmail D, Wissel J, Laffont I, Simon O, Scheschonka A, Flatau-Baqu? B, Dressler D, Simpson DM. Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus. Ann Phys Rehabil Med. 2021 Mar; 64(2):101376.
Score: 0.067
-
Wissel J, Bensmail D, Scheschonka A, Flatau-Baqu? B, Simon O, Althaus M, Simpson DM. Post hoc analysis of the improvement in shoulder spasticity and safety observed following treatment with incobotulinumtoxinA. J Rehabil Med. 2020 Mar 18; 52(3):jrm00028.
Score: 0.066
-
Turner-Stokes L, Ashford S, Esquenazi A, Wissel J, Ward AB, Francisco G, Lains J, Suputtitada A, Serrano S, Baguley IJ, Barnes M, Simpson DM. A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework. Eur J Phys Rehabil Med. 2018 Aug; 54(4):605-617.
Score: 0.057
-
Esquenazi A, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Graham GD, McGuire JR, Odderson IR, Patel AT, Simpson DM. OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a?Delphi Panel Approach. PM R. 2017 Oct; 9(10):960-968.
Score: 0.054
-
Simpson DM, Patel AT, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Esquenazi A, Graham GD, McGuire JR, Odderson I. OnabotulinumtoxinA Injection for Poststroke Upper-Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process. PM R. 2017 02; 9(2):136-148.
Score: 0.051
-
Simpson DM, Rice AS, Emir B, Landen J, Semel D, Chew ML, Sporn J. A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy. Pain. 2014 Oct; 155(10):1943-54.
Score: 0.044
-
Simpson DM, Brown S, Tobias JK, Vanhove GF. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Clin J Pain. 2014 Feb; 30(2):134-42.
Score: 0.043
-
Thomas AM, Simpson DM. Contralateral weakness following botulinum toxin for poststroke spasticity. Muscle Nerve. 2012 Sep; 46(3):443-8.
Score: 0.039
-
Simpson DM, Gazda S, Brown S, Webster LR, Lu SP, Tobias JK, Vanhove GF. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage. 2010 Jun; 39(6):1053-64.
Score: 0.034
-
Prasad S, Harman R, Henderson R, Chunnilal S, Simpson D. Laparoscopic splenectomy and the treatment outcomes for idiopathic thrombocytopaenic purpura at North Shore Hospital. N Z Med J. 2009 Jun 19; 122(1297):38-48.
Score: 0.032
-
Cikurel K, Schiff L, Simpson DM. Pilot study of intravenous immunoglobulin in HIV-associated myelopathy. AIDS Patient Care STDS. 2009 Feb; 23(2):75-8.
Score: 0.031
-
Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009 Apr; 80(4):380-5.
Score: 0.030
-
Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008 Jun 10; 70(24):2305-13.
Score: 0.029
-
Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 06; 70(19):1691-8.
Score: 0.029
-
Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 06; 70(19):1699-706.
Score: 0.029
-
Simpson DM, Estanislao L, Brown SJ, Sampson J. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J Pain Symptom Manage. 2008 Mar; 35(3):299-306.
Score: 0.028
-
Verma S, Estanislao L, Mintz L, Simpson D. Controlling neuropathic pain in HIV. Curr HIV/AIDS Rep. 2004 Sep; 1(3):136-41.
Score: 0.023
-
Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, Baird BJ, Barrett P, Hammer AE. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003 May 13; 60(9):1508-14.
Score: 0.021
-
Guo ZN, Qu Y, Gao Y, Xing Y, Ma H, Liu J, Guo YZ, Chang J, Zhang P, Jin H, Sun X, Han K, Hu HH, He Q, Simpson DM, Yang Y. Changes in cerebral autoregulation, stroke-related blood biomarkers, and autonomic regulation after patent foramen ovale closure in severe migraine patients. CNS Neurosci Ther. 2023 10; 29(10):3031-3042.
Score: 0.021
-
Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022 06; 63(6):1375-1386.
Score: 0.019
-
Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-na?ve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022 03; 196(5):1209-1218.
Score: 0.019
-
Bailey RJ, Erekson DM, Cattani K, Jensen D, Simpson DM, Klundt J, Vogeler HA, Schmuck D, Worthen VE, Caldwell Y, Beecher ME, Griner D, Hobbs K. Adapting stepped care: Changes to service delivery format in the context of high demand. Psychol Serv. 2022 Aug; 19(3):494-501.
Score: 0.018
-
Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 03; 34(3):787-798.
Score: 0.016
-
Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 09 12; 134(11):851-859.
Score: 0.016
-
Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep; 6(9):e459-e469.
Score: 0.016
-
Livelli A, Vaida F, Ellis RJ, Ma Q, Ferrara M, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Sacktor N, Simpson DM, Grant I, Letendre SL. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 07; 6(7):e456-e462.
Score: 0.016
-
Gracies JM, Simpson D. Neuromuscular blockers. Phys Med Rehabil Clin N Am. 1999 May; 10(2):357-83, viii.
Score: 0.016
-
P?rez-Valero I, Ellis R, Heaton R, Deutsch R, Franklin D, Clifford DB, Collier A, Gelman B, Marra C, McCutchan JA, Navis A, Sacktor N, Simpson D, Grant I, Letendre S. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS. 2019 03 01; 33(3):475-481.
Score: 0.015
-
Broderick P, Horgan F, Blake C, Ehrensberger M, Simpson D, Monaghan K. Mirror therapy and treadmill training for patients with chronic stroke: a pilot randomized controlled trial. Top Stroke Rehabil. 2019 04; 26(3):163-172.
Score: 0.015
-
Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305.
Score: 0.015
-
Broderick P, Horgan F, Blake C, Ehrensberger M, Simpson D, Monaghan K. Mirror therapy for improving lower limb motor function and mobility after stroke: A systematic review and meta-analysis. Gait Posture. 2018 Jun; 63:208-220.
Score: 0.015
-
Chanan-Khan AA, Zaritskey A, Egyed M, Vokurka S, Semochkin S, Schuh A, Kassis J, Simpson D, Zhang J, Purse B, Fo? R. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2017 Nov; 4(11):e534-e543.
Score: 0.014
-
O'Dell MW, Brashear A, Jech R, Lejeune T, Marque P, Bensmail D, Ayyoub Z, Simpson DM, Volteau M, Vilain C, Picaut P, Gracies JM. Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study. PM R. 2018 01; 10(1):1-10.
Score: 0.014
-
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21.
Score: 0.013
-
Li AY, Woulfe T, Rolfe-Vyson V, Rowland V, Simpson D, Merriman E. Management and outcomes of axial isolated distal deep vein thrombosis at North Shore Hospital, New Zealand: a retrospective audit. Intern Med J. 2015 Feb; 45(2):177-82.
Score: 0.012
-
Mehta D, Barnett M, Zhou L, Woulfe T, Rolfe-Vyson V, Rowland V, Simpson D, Merriman E. Management and outcomes of single subsegmental pulmonary embolus: a retrospective audit at North Shore Hospital, New Zealand. Intern Med J. 2014 Sep; 44(9):872-6.
Score: 0.011
-
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Foss? A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug; 15(9):966-74.
Score: 0.011
-
Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 08; 123(19):2944-52.
Score: 0.011
-
Harrison T, Miyahara S, Lee A, Evans S, Bastow B, Simpson D, Gilron I, Dworkin R, Daar ES, Wieclaw L, Clifford DB. Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies. Pain Med. 2013 Jul; 14(7):1039-47.
Score: 0.010
-
Dorfman D, George MC, Schnur J, Simpson DM, Davidson G, Montgomery G. Hypnosis for treatment of HIV neuropathic pain: a preliminary report. Pain Med. 2013 Jul; 14(7):1048-56.
Score: 0.010
-
Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013 Jun 01; 67:94-114.
Score: 0.010
-
Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal KR, Simpson DM, Smith CP, Ward AB. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon. 2013 Jun 01; 67:115-28.
Score: 0.010
-
Vinti M, Costantino F, Bayle N, Simpson DM, Weisz DJ, Gracies JM. Spastic cocontraction in hemiparesis: effects of botulinum toxin. Muscle Nerve. 2012 Dec; 46(6):926-31.
Score: 0.010
-
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstr?m B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gr?nhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25; 377(9784):2181-92.
Score: 0.009
-
Attal N, Bouhassira D, Baron R, Dostrovsky J, Dworkin RH, Finnerup N, Gourlay G, Haanpaa M, Raja S, Rice AS, Simpson D, Treede RD. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain. 2011 May; 15(5):441-3.
Score: 0.009
-
Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011 Feb; 17(1):3-16.
Score: 0.009
-
Dobkin BH, Landau WM, Sahrmann S, Thomas Thach W, Simpson DM, Gracies JM, Graham K, Hallett M, Miyasaki J, Naumann M, Russman B, Simpson L, So Y. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Neurology. 2009 Sep 01; 73(9):736; author reply 737-8.
Score: 0.008
-
Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, Jarvik JG, Miller EN, Singer EJ, Ellis RJ, Kolson DL, Simpson D, Nath A, Berger J, Shriver SL, Millar LL, Colquhoun D, Lenkinski R, Gonzalez RG, Lipton SA. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007 Sep 12; 21(14):1877-86.
Score: 0.007
-
Evans SR, Simpson DM, Kitch DW, King A, Clifford DB, Cohen BA, McArthur JC. A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One. 2007 Jul 25; 2(6):e551.
Score: 0.007
-
Estanislao L, Carter K, McArthur J, Olney R, Simpson D. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr. 2004 Dec 15; 37(5):1584-6.
Score: 0.006
-
Paquette DW, Simpson DM, Friden P, Braman V, Williams RC. Safety and clinical effects of topical histatin gels in humans with experimental gingivitis. J Clin Periodontol. 2002 Dec; 29(12):1051-8.
Score: 0.005
-
Post MJ, Yiannoutsos C, Simpson D, Booss J, Clifford DB, Cohen B, McArthur JC, Hall CD. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol. 1999 Nov-Dec; 20(10):1896-906.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|